In the research literature, retatrutide (GLP-3 RT) — a triple GLP-1/GIP/glucagon receptor agonist — reached up to 24.2% mean weight reduction at 48 weeks in its Phase 2 obesity trial, while tirzepatide (GLP-2 TRZ), a dual GLP-1/GIP agonist, reached 22.5% at 72 weeks (15 mg) in SURMOUNT-1. These are cross-trial figures, not a head-to-head result. The difference traces to retatrutide's added glucagon receptor arm. Tirzepatide is the appropriate tool for dual-receptor questions and is the only one of the two that is FDA approved. The first direct comparison — the Phase 3 TRIUMPH-5 trial — is expected to complete in December 2026. Which is "better" depends entirely on the research endpoint.
Research Use Only (RUO). Not for human consumption. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
The whole comparison reduces to one variable: how many receptors each molecule engages. Tirzepatide (GLP-2 TRZ) is a dual agonist — it activates the GLP-1 receptor and the GIP receptor with a single 39-amino-acid, fatty-acid-modified peptide. Retatrutide (GLP-3 RT) is a triple agonist — it adds agonism at the glucagon receptor on top of those same two targets.
That third target is not incremental. Glucagon receptor activation in liver hepatocytes drives gluconeogenesis, raises hepatic energy expenditure through futile metabolic cycling, and supports lipid oxidation. In retatrutide research, this glucagon arm is associated with elevated total daily energy expenditure beyond what weight-matching predicts, and with substantial hepatic lipid reduction in NAFLD/MASLD models. So these are not "weak version vs strong version" of one drug — they engage overlapping but non-identical pharmacology, which is exactly why the right choice depends on what you're studying.
| Attribute | Tirzepatide GLP-2 TRZ |
Retatrutide GLP-3 RT |
|---|---|---|
| Receptor targets | GLP-1 + GIP (dual) | GLP-1 + GIP + glucagon (triple) |
| Class | Dual incretin agonist | Triple incretin agonist |
| Peak weight reduction (trial) | 22.5% — 15 mg, 72 wk (SURMOUNT-1) | 24.2% — 12 mg, 48 wk (Phase 2) |
| Glucagon / energy-expenditure arm | None | Yes — elevated TDEE in models |
| Hepatic steatosis signal | Reduction reported | Up to ~82% reduction (Phase 2a MASLD) |
| Regulatory status | FDA approved (Mounjaro / Zepbound) | Investigational — not FDA approved |
| Approx. elimination half-life | ~5 days | ~6 days |
| Head-to-head trial | TRIUMPH-5 (NCT06662383) — primary completion est. Dec 2026 | |
| Research catalog | Shop GLP-2 TRZ → | Shop GLP-3 RT → |
Because no head-to-head result has published yet, every comparison today is cross-trial — different populations, durations, and dosing — a real limitation, not a footnote. With that caveat, the directional signal is consistent across the literature.
Two things to read carefully here. First, tirzepatide is not a weak baseline — a 2024 meta-analysis reaffirmed its superiority over earlier single-agonist agents like semaglutide, so retatrutide's edge on body composition is clearing an already-high bar. Second, reported side-effect profiles for both are dominated by dose-escalation GI effects. One differentiator under active observation: a transient heart-rate elevation noted in retatrutide trials that is not characteristic of tirzepatide's GIP/GLP-1 action — a point the TRIUMPH Phase 3 program is tracking.
"More weight loss" is a clinical-outcome lens. For laboratory research, the relevant question is which receptor profile matches your endpoint — not which produces a bigger number. A glucagon-arm or energy-expenditure study needs GLP-3 RT; a clean dual-incretin study needs GLP-2 TRZ.
The single most important fact most comparison pages omit: a direct, randomized, double-blind Phase 3 trial comparing retatrutide to tirzepatide in adults with obesity is already running. It is registered as TRIUMPH-5 (NCT06662383), sponsored by Eli Lilly, started November 2024, with a primary completion estimate of December 2026. Until that data publishes, anyone claiming a definitive winner is extrapolating from cross-trial comparison. This page will be updated when results are available.
Choose tirzepatide when the research question is confined to dual GLP-1/GIP receptor pharmacology and you want to isolate it from glucagon-axis confounds. It's also the right tool when you need the molecule with the deepest published characterization and an FDA-approved comparator for benchmarking. If your endpoint is glucose regulation or GIP-specific adipose signaling rather than maximal energy expenditure, retatrutide's added glucagon arm is noise, not signal. Background and mechanism detail live in the GLP-2 TRZ research guide.
Choose retatrutide when the glucagon receptor and integrated energy expenditure are part of the question — total daily energy expenditure, hepatic lipid handling in MASLD models, or maximal body-composition change. It's also the molecule of interest for researchers tracking the leading edge of multi-receptor agonist pharmacology, since it represents the current frontier beyond dual agonism. Full mechanism and Phase 2 detail are in the GLP-3 RT research guide.
Both are long-acting peptides with comparable half-lives (~5 days for tirzepatide, ~6 days for retatrutide), so reconstitution and storage handling are effectively identical. Both should be reconstituted with bacteriostatic water, stored refrigerated after reconstitution, protected from light, and shielded from repeated freeze-thaw. The operational difference in a parallel study is minor; the scientific difference in receptor coverage is the variable that matters.
If your design compares dual vs triple agonism directly, match concentrations and reconstitution protocol across both arms so receptor count is the only variable. Source both from the same supplier and batch window where possible so COA methodology stays consistent.
Tirzepatide is FDA approved as a human therapeutic, but research-grade material for laboratory work is sold under research-use-only labeling as GLP-2 TRZ. Retatrutide is not FDA approved and is available for preclinical work as GLP-3 RT through the same channel. For both, the variables that actually determine research utility are third-party COA depth, verified purity (99%+), and batch consistency — not the headline price. A cheaper vial with a shallow or absent COA is a false economy when your data depends on knowing exactly what's in it. Every Evo Peptides batch ships with a third-party Certificate of Analysis.
Every vial third-party tested at 99%+ purity, COA included. Same-day shipping before 3:00 PM CST · Free shipping over $200 · Wisconsin fulfillment.
In published trials, retatrutide (GLP-3 RT) reached up to 24.2% mean weight reduction at 48 weeks in its Phase 2 obesity trial, while tirzepatide (GLP-2 TRZ) reached 22.5% at 72 weeks at the 15 mg dose in SURMOUNT-1. These are cross-trial figures, not a head-to-head result, so direct comparison is limited. The added glucagon receptor agonism is the mechanistic driver. Whether "stronger" is the right word depends on the research endpoint, since the two engage overlapping but non-identical pharmacology.
GLP-2 TRZ is the research catalog name for tirzepatide (dual GLP-1/GIP agonist). GLP-3 RT is the catalog name for retatrutide (triple GLP-1/GIP/glucagon agonist). The numerals refer to how many receptors each molecule engages, not to different GLP isoforms.
A direct Phase 3 trial, TRIUMPH-5 (NCT06662383), is underway, sponsored by Eli Lilly, with primary completion estimated December 2026. Until it publishes, all comparison is cross-trial and limited by differences in design, population, and duration.
Tirzepatide is FDA approved (Mounjaro, Zepbound). Retatrutide remains investigational and is not FDA approved. For research sourcing, both are available under research-use-only labeling.
No meaningful difference. Both are long-acting peptides (~5–6 day half-life) reconstituted with bacteriostatic water, stored refrigerated after reconstitution, kept out of light, and protected from repeated freeze-thaw.